Home > Haematology > ASH 2019 > Late-Breaking Abstracts > Adding daratumumab to carfilzomib/dexamethasone prolongs PFS and OS in R/R MM

Adding daratumumab to carfilzomib/dexamethasone prolongs PFS and OS in R/R MM

Presented By
Prof. Saad Usmani, UNC-Chapel Hill School of Medicine, USA
Conference
ASH 2019
Trial
Phase 3, CANDOR
In the open-label randomised phase 3 CANDOR trial, the addition of anti-CD38 antibody daratumumab to carfilzomib and dexamethasone reduced the risk of disease progression or death by 37% compared with carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma (MM). Prof. Saad Z. Usmani (UNC-Chapel Hill School of Medicine, USA) presented the initial results of the trial, which randomised 466 patients (2:1 ratio) with relapsed/refractory MM previously treated with 1 to 3 prior therapies to either daratumumab + carfilzomib/dexamethasone (n=312) or carfilzomib/dexamethasone alone (n=154) [1]. The primary endpoint of this study was progression-free survival (PFS). Key secondary endpoints were overall response rate, minimal residual disease-negative status, complete response rate at 12 months, overall survival (OS), duration of response, an...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on